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ICH guidelines were acceptable over the concentration range 
of 2-12 μg/mL for both drugs. Mean centering was performed 
using Minitab® program. Using computer assisted programs 
after spiking accompanied with direct UV measurement of 
the drugs was satisfactory for accurate assay without complex 
instrumentations. The optimized method was proved to be 
suitable for industrial QC labs.
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ABSTRACT
Introduction of computer-assisted analysis to pharmaceutical 
products is considered a significant approach. A new method 
was developed for simultaneous determination of empagliflozin 
and metformin manipulating their ratio spectra with 
application on recently approved pharmaceutical combination, 
Synjardy® tablets. Spiking technique was used to increase the 
concentration of empagliflozin after extraction from tablets 
to allow its simultaneous determination with metformin 
without prior separation. Validation parameters according to 
1. Introduction:
Synjardy® is composed of empagliflozin from the gliflozin 
class that was recently approved for the treatment of type 
2 diabetes as a sodium glucose co-transporter 2 inhibitor 
enhancing urinary glucose excretion [1] and metformin 
which is the drug of choice in mixed therapy for type 2 
diabetes. Only one chromatographic method [2] and one 
spectrophotometric method [3] were developed for its 
pharmaceutical analysis. The aim of the present work is to 
present a new simple computer-assisted mean centering 
method [4] for the analysis of empagliflozin and metformin 
taking in consideration the spiking criteria. Spiking technique 
was used to increase the concentration of empagliflozin after 
extraction from tablets allowing its determination despite its 
low contribution.
Spectrophotometric assays for some recently approved anti-
diabetic drugs (Table 1) showed more facilitated, simple 
and cost effective methods [5-11]. Furthermore, it showed 
the advantages of low cost solvents, shorter analysis time 
and simple instrumentation instead of complex details 
implemented in the chromatographic method development. 
Spectrophotometric analysis exhibited more economic and 
simple assays [5-11] either using direct UV determination or 
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by manipulation of the obtained spectra with acceptable limit 
of detection (LOD) and limit of quantification (LOQ) values 
that ensured satisfying sensitivity. Mostly used solvents were 
distilled/deionized water and methanol. The applications of 
cost effective spectrophotometric methods have renovated 
the concept of analysis in a highly accurate and precise way.
2. Experimental
2.1. Instrumentation
JASCO® double-beam UV spectrophotometer (S/N 
C367961148, Japan) supported with Spectra Manager® 
software were used.
2.2. Reagents, reference standard samples and working 
solutions
Empagliflozin certified to contain 99.70 %, metformin 
certified to contain 99.80 % and Synjardy® tablets 
nominally containing 12.5 mg of empagliflozin and 500 
mg of metformin per tablet were supplied from Boehringer 
Ingelheim (Germany). Working solutions (20 µg/mL) were 
prepared in methanol.
2.3. Sample preparation
The coats of ten Synjardy® tablets were carefully removed and 
then the tablets were powdered and mixed. An accurately 
weighed amount equivalent to 2.5 mg of empagliflozin and 
100 mg of metformin was made up to 100 mL with methanol, 
sonicated to dissolve and filtered. One mL of the extract was 
transferred to a 100 mL volumetric flask, spiked with 10 mL 
of empagliflozin working solution and finally completed to 
volume with methanol.
2.4. Procedure
2.4.1. Preliminary investigation
Zero-order absorption spectra of empagliflozin (8 µg/mL) 
and metformin (8 µg/mL) were recorded separately against 
methanol as a blank showing the maximum absorption (λmax) 
at 225 nm and 237 nm, respectively (Figure 1).
2.4.2. Linearity
Accurately measured aliquots of working solutions equivalent 
to 20-120 µg of each drug were transferred separately into a 
series of 10 mL volumetric flasks, completed to volume with 
methanol. The previously scanned spectra of empagliflozin 
and metformin were divided separately by (10 µg/mL of 
metformin) and (12 µg/mL of empagliflozin, respectively. 
The obtained ratio spectra were mean centered and then the 
mean centered values of empagliflozin and metformin were 
measured at 221.8 nm and 249.2 nm, respectively. Calibration 
curves were attained by plotting the mean centered values 
against concentration.
2.4.3. Assay of laboratory prepared mixtures
Three different ratios (1:3, 1:1 and 3:1) of the laboratory 
prepared mixtures were prepared using concentrations 
equivalent to (3, 6, 9 µg/mL) and (9, 6, 3 µg/mL) of 
empagliflozin and metformin, respectively. The zero order 
spectra of each mixture were recorded using methanol as 
blank. Then obtained spectra were divided by (10 µg/mL 
of metformin) and (12 µg/mL of empagliflozin) separately 
in order to get the ratio spectra that will be manipulated by 
the mean centering method to calculate the corresponding 
concentration of each drug. The ratio spectra divided by 
metformin were mean centered using Minitab® program. 
Table 1. Spectrophotometric methods for analysis of some recently approved anti-diabetic drugs in pharmaceutical 
formulations namely linagliptin and alogliptin.
Method Detection wavelength Linearity (µg/mL) Application
Direct UV 277 nm 2-6 Assay of linagliptin in Glyxambi® tablet (5)
Direct UV 294 nm 5-25 Assay of linagliptin in Tradjenta® tablets (6)
Direct UV 241 nm 10-35 Assay of linagliptin in Tradjenta® tablets (7)
Direct UV 276 nm 5-35 Assay of alogliptin in Nesina® tablets (8)
Simultaneous equation 224 nm 0.5-18 Assay of alogliptin in Kazano® tablets (9)
Absorption ratio 251 nm 0.5-18 Assay of alogliptin in Kazano® tablets (9)
First derivative 222 nm 2-16 Assay of alogliptin in Nesina® tablets (10)
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The mean centered values were measured at 221.8 nm for 
empagliflozin determination, while the mean centered values 
of the ratio spectra divided by empagliflozin were used for 
determination of metformin by measuring the mean centered 
values at 249.2 nm.
2.4.4. Accuracy, repeatability and intermediate precision
The laboratory prepared mixtures prepared under 2.4.3 were 
analyzed using the proposed method three times within the 
same day and on three successive days. The mean of the 
percent recoveries (R %) and the percent relative standard 
deviation (RSD %) were then calculated for each method.
2.4.5. Assay of Synjardy® tablets
The absorbance spectrum of the tablet extract prepared 
under section 2.3 was recorded using methanol as blank. The 
obtained spectra were divided by (10 µg/mL metformin) and 
(12 µg/mL empagliflozin) separately in order to record the 
ratio spectra that will be manipulated by the mean centering 
method to calculate the corresponding concentration of each 
drug as discussed under (section 2.4.3).
2.4.6. Forced degradation of empagliflozin
Forced degradation study of empagliflozin, as a recently 
approved drug, included solid state (thermal and photo-
degradation) and solution state (acid, alkali and H2O2) stress 
conditions were performed. To a series of test tubes, each one 
contains 2.5 mL of working solution, 2.5 mL of 0.3% H2O2, 1N 
NaOH and 1N HCl were added separately and heated at 60 ◦C 
for 0.5 h, then the acid and alkali mixtures were neutralized 
and each mixture was completed to 10 mL with methanol. 
The dry powder of empagliflozin was placed in oven at 55 ◦C 
for 6 h & placed under UV lamp for 6 h and then dissolved in 
methanol to give a proposed concentration of 5 µg/mL.
3. Results and discussion
The absorption spectra of each drug were divided by the 
spectrum of a selected divisor (the other drug) to get the 
ratio spectra, then mean centering method [4] was applicable 
as empagliflozin and metformin are non-interactive drugs 
and each of them obey Beer’s law according to the following 
equation (Va = AEG CEG + AMT CMT). Where, Va is the vector of 
absorbance, (AEG - AMT) are the molar absorptivities, (CEG - 
CMT) are the concentrations of empagliflozin and metformin, 
Figure 1. Overlay of the absorption spectra of EG (8 µg/mL) and MT (8 µg/mL), using methanol as a blank.
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respectively. After division over AMT, the produced ratio 
spectra will be mean centered; CMT will be zero value 
enabling the determination of CEG without interference from 
metformin and the same concept regarding AEG.
The obtained absorption spectra of both empagliflozin 
and metformin were divided by the spectrum of 10 μg/mL 
metformin and 12 μg/mL empagliflozin, respectively and 
then mean centered using Minitab® program (Figure 2). 
Empagliflozin and metformin were determined at 221.8 nm 
and 249.2 nm, respectively in a concentration range of 2-12 
μg/mL.
All the validation parameters were found to be compatible 
with ICH guidelines [12]. The validity of the calibration 
curves over the concentration range (2-12 μg/mL) was 
validated by the obtained low values of LOD - LOQ 
parameters, and acceptable values of STEYX, Sb & Sa as 
shown in (Table 2). Where; LOD is the limit of detection 
which represents drug concentration at STEYX/S ratio of 3.3, 
LOQ is the limit of quantification at which STEYX/S is 10, 
STEYX is the residual standard deviation of the regression 
line, Sb is the standard deviation of the slope and Sa is the 
standard deviation of the intercept. Also the developed 
method was adopted successfully for determination of the 
investigated drugs in laboratory prepared mixtures (Figure 
2).
Influence of different variables was studied, including 
scanning speed, wavelength of measurements, divisor 
concentration and smoothing factor. Different concentrations 
of both drugs (6, 8, 10, 12, 14 and 16 μg/mL) were tried as 
divisors. Concentration of 12 μg/mL empagliflozin and 10 
μg/mL metformin were selected as the best divisors with 
minimum noise. No significant difference was found using 
different smoothing factors, so it was excluded from the 
method.
Figure 2. The mean centered values of the ratio spectra representing (2-12 μg/mL) EG divided by 10 μg/mL MT (a), the ratio 
spectra of (2-12 μg/mL) MT divided by 12 μg/mL EG (b) and the ratio spectra of the laboratory prepared mixtures divided 
separately by 10 μg/mL MT (c), and 12 μg/mL EG (d).
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Table 2. Results obtained by the proposed mean centering method
Item Empagliflozin Metformin
Wavelength of measurements 221.8 nm 249.2 nm
Linearity range 2-12 μg/mL 2-12 μg/mL
Regression equation Mv = 0.0404 Cμg/mL + 0.0024 Mv = 0.9338 Cμg/mL + 0.0391
Correlation coefficient (r) 0.9998 0.9999
Sb 1.7 x 10-4 0.004
Sa 1.6 x 10-3 0.04
C.I. of the slope 0.0404 ± 7 x 10-6 0.9338 ± 3.8 x 10-3
C.I. of the intercept 0.0024 ± 3.97 x 10-6 0.0391 ± 1.5 x 10-3
STEYX 0.0014 0.034
LOD (μg/mL) 0.11 0.12
LOQ (μg/mL) 0.34 0.36
Accuracy (Mean ± SD) 99.88 % ± 0.62 100.09 % ± 0.55
Intraday RSD % 0.17-0.22 0.10-0.23
Interday RSD % 0.13-0.18 0.12-0.27
Drug in dosage form (Mean ± SD) 96.44 % ± 0.35 99.96 % ± 0.32
with F = 0.001, P = 0.977 for empagliflozin and F = 0.335, P 
= 0.594 for metformin.
Table 3. One way ANOVA results at P<0.05 for the proposed 
method for determination of empagliflozin and metformin 
against reference method [3].
Empagliflozin Metformin
Groups Mean S.D. Mean S.D.
*Reference method [3] 99.86 0.95 100.48 1.03
*Proposed method 99.88 0.62 100.09 0.55
*Studied groups showed no significant difference at P>0.05, with 
F = 0.001, P = 0.977 for empagliflozin and F = 0.335, P = 0.594 for 
metformin.
Abbreviations: S.D. = standard deviation
4. Conclusion
The proposed analytical method proved to be accurate 
for determination of empagliflozin and metformin as an 
economic assay based on simple instruments and computer 
assisted programs. The methods were applied successfully on 
the pharmaceutical dosage form with acceptable validation 
results. Spiking technique was crucial in the developed 
method which allowed the direct measurement of the minor 
component in the mixture. The developed method should 
be of interest to the analysts in the area of drug control and 
can be used by QC laboratories for the analysis of recently 
approved Synjardy® tablets.
Where Mv is the mean centered value, C is the concentration 
of the drug, Sb is the standard error of slope, Sa is the standard 
error of intercept, C.I. is the confidence interval, STEYX is 
the residual standard deviation of the regression line, LOD 
is the limit of detection, LOQ is the limit of quantification, 
SD is the standard deviation, RSD % is the percent relative 
standard deviation.
Accuracy of the results was checked by calculating the 
percent recovery of different concentrations of each 
drug in laboratory prepared mixtures. The mean of the 
recovery and standard deviations were shown in (Table 2). 
Precision of the methods was checked using intraday and 
interday records of the same laboratory prepared mixtures. 
The RSD % of recoveries was calculated and found to be 
less than 1%.
To check the specificity of the method, each drug was 
determined in laboratory prepared mixture and in Synjardy® 
tablets in the presence of excipients including copovidone, 
corn starch, colloidal silicon dioxide, magnesium stearate, 
hypromellose, titanium dioxide, talc, polyethylene glycol 400 
and ferric oxide. And the results are shown in (Table 2). The 
forced degradation study showed 24 % degradation in case of 
alkaline stress conditions, 5 % in case of acidic degradation 
and no degradation behavior was observed under the applied 
oxidative, thermal and photo-degradation conditions as a 
required specificity for the validated procedure. Statististical 
analysis (Table 3) showed no significant difference in 
comparison to a spectrophotometric method [3] at P>0.05, 
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